1. Clinical & Scientific Overview
Disodium Hydrogen Citrate (TIP-MED-000430, Reference Code [12.11]-C160) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [12.11] (Potassium Magnesium Citrate & Disodium Hydrogen Citrate). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.11], p. 160): Disodium Hydrogen Citrate: Citralka (Pfizer — 1.53 g/5 mL), Alkasol (Stadmed — 1.4 g/5 mL), Orikind; Potassium Magnesium Citrate: Potrate-MB6 (Intas), Orocit-K, Ston-1 — Strengths & Dosage Forms: Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
3. Mechanism of Action & Pharmacodynamics
Citrate is metabolised to bicarbonate in the liver, raising urinary pH (6.5–7.2) to solubilise uric acid/cystine and chelating urinary calcium to inhibit calcium oxalate nucleation.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and dissolution of renal calculi (calcium oxalate, uric acid, and cystine nephrolithiasis), symptomatic relief of burning micturition (dysuria) in UTI, and urinary alkalinisation during uricosuric/allopurinol gout therapy
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Disodium Hydrogen Citrate Liquid: Adult 10–15 mL (2–3 teaspoons) diluted in 1 full glass (200 mL) of water TDS–QDS after meals; Paediatric (6–12 yr) 5 mL diluted in water BD–TDS. Potassium Magnesium Citrate: 10–15 mL diluted in water BD–TDS after meals (or 1–2 ER tablets BD).
Administration & Meal Timing: MUST be diluted in a full glass of water and taken 15–30 minutes AFTER meals to prevent gastric mucosal irritation and osmotic diarrhoea. | 2 to 4 times daily after meals and at bedtime.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [12.11].
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
7. Contraindications, Precautions & High-Risk Warnings
- HYPERKALAEMIA vs SODIUM LOAD SELECTION RULE: Potassium Citrate preparations are CONTRAINDICATED in CKD Stage G4–G5 (eGFR <30 mL/min), hyperkalaemia (K+ >5.0 mEq/L), or with Spironolactone/ACEi/ARBs. Disodium Hydrogen Citrate delivers a high sodium load (~16 mmol Na+ per 10 mL) — avoid in severe heart failure, oedema, or uncontrolled hypertension!
Key Clinical Precautions: Renal: Contraindicated if eGFR <30 mL/min, oliguria, or acute kidney injury. Hepatic: Avoid in decompensated cirrhosis with ascites.
8. Adverse Effects Profile
- Mild nausea, abdominal bloating, loose stools (if taken undiluted), wax-matrix ghost tablet in stool (ER tablets).
- Life-threatening hyperkalaemic cardiac arrhythmia (Potassium Citrate in CKD/MRA patients), fluid overload/pulmonary oedema (Disodium Hydrogen Citrate in HFrEF), metabolic alkalosis (over-alkalinisation >pH 7.5 precipitates calcium phosphate stones!).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Potassium Citrate + ACEi/ARB/Spironolactone/Trimethoprim = severe hyperkalaemia
- Urinary alkalinisation increases renal excretion of Salicylates/Phenobarbitone and decreases excretion of Quinolones/Ephedrine; aluminium antacids + citrate increase systemic Al3+ neurotoxicity in CKD!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.11].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: NEVER swallow the liquid syrup neat — always mix the measured dose in 1 full glass of water and drink after food; drink 10–12 glasses of water daily to flush kidney crystals.
- Meal & Clock Timing Instruction: MUST be diluted in a full glass of water and taken 15–30 minutes AFTER meals to prevent gastric mucosal irritation and osmotic diarrhoea. (2 to 4 times daily after meals and at bedtime.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Non-Schedule / Schedule H (Strength-dependent) | NLEM 2022: NFI 2026 Standard Formulary | Compendia: NFI 7th Ed 2026 / EAU Urolithiasis Guidelines
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Disodium Hydrogen Citrate Oral Liquid: 1.25 g to 1.53 g per 5 mL (100 mL, 200 mL bottle). Potassium Citrate (1100 mg = ~10 mEq K+) + Magnesium Citrate (375 mg) + Pyridoxine (20 mg) Oral Solution / ER Tablets.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.11]-CMP161 Phenazopyridine Hydrochloride IP — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors
- [12.12]-C162 Tadalafil — Selective Phosphodiesterase Type-5 (PDE5) Inhibitor (Pulmonary Va
- [12.1] Tamsulosin Hydrochloride (and Silodosin / Alfuzosin comparison) — Uroselective Alpha-1A and Alpha-1D Adrenoceptor Antagonist (Relax
- [12.2] Finasteride (and Dutasteride comparison) — 5-Alpha-Reductase Inhibitor (5-ARI; Blocks Intracellular Conversi